MARKET

SLS

SLS

Sellas Life Sciences Group Inc
NASDAQ
1.080
-0.030
-2.70%
Closed 19:59 03/31 EDT
OPEN
1.110
PREV CLOSE
1.110
HIGH
1.119
LOW
1.050
VOLUME
1.46M
TURNOVER
--
52 WEEK HIGH
1.840
52 WEEK LOW
0.7720
MARKET CAP
98.11M
P/E (TTM)
-2.1403
1D
5D
1M
3M
1Y
5Y
1D
Sellas Life Sciences: A Hold For Now With Huge, But Uncertain, Near-Term Catalyst
Seeking Alpha · 13h ago
Weekly Report: what happened at SLS last week (0324-0328)?
Weekly Report · 22h ago
Sellas Life Sciences Advances in Cancer Treatment Development
TipRanks · 5d ago
Promising Clinical Advancements and Financial Stability Position SELLAS Life Sciences Group for Growth
TipRanks · 6d ago
Weekly Report: what happened at SLS last week (0317-0321)?
Weekly Report · 03/24 09:57
SELLAS Life Sciences GAAP EPS of -$0.50 beats by $0.04
Seeking Alpha · 03/20 20:37
SELLAS Life Sciences Gr FY 2024 GAAP EPS $(0.50) Beats $(0.54) Estimate
Benzinga · 03/20 20:15
*SELLAS Life Sciences 2024 Loss/Shr 50c >SLS
Dow Jones · 03/20 20:12
More
About SLS
More
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of therapeutics for a range of cancer indications. The Company's product candidates are galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor. GPS is a cancer immunotherapeutic agent licensed by Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is developing SLS009, which is licensed by GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of mainland China, Hong Kong, Macau, and Taiwan.
Recently
Symbol
Price
%Change

Webull offers Sellas Life Sciences Group Inc stock information, including NASDAQ: SLS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SLS stock methods without spending real money on the virtual paper trading platform.